US Stock MarketDetailed Quotes
TARO Taro Pharmaceutical Industries
- 42.970
- 0.0000.00%
Close Jun 25 09:30 ET
1.27BMarket Cap30.05P/E (TTM)
0.000High0.000Low0Volume0.000Open42.970Pre Close0.00Turnover0.00%Turnover Ratio30.05P/E (Static)29.50MShares45.76052wk High0.71P/B347.45MFloat Cap32.67052wk Low--Dividend TTM8.09MShs Float150.996Historical High--Div YieldTTM0.00%Amplitude1.637Historical Low--Avg Price1Lot Size
Taro Pharmaceutical Industries Key Stats
Quarterly+Annual
YOY
| (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 292.30%124.56M | -32.33%38.34M | 142.23%30.93M | 133.37%47.52M | 113.40%7.78M | 120.01%31.75M | 37.31%56.65M | 106.65%12.77M | 139.14%20.36M | -231.90%-58.03M |
| Net income from continuing operations | 111.70%53.87M | 118.14%15.08M | 178.08%20.21M | 403.87%8.55M | -28.74%10.03M | -56.33%25.45M | -74.78%6.91M | -72.38%7.27M | -112.06%-2.81M | 175.02%14.08M |
| Operating gains losses | -103.58%-86K | -45.75%453K | -416.67%-741K | 89.03%1.16M | -231.81%-953K | 714.58%2.4M | 327.52%835K | 135.19%234K | -56.36%611K | 195.26%723K |
| Depreciation and amortization | -3.22%31.09M | -23.92%8.22M | 0.66%7.37M | 8.41%7.61M | 13.10%7.89M | 23.97%32.13M | 62.10%10.81M | 13.53%7.33M | 8.79%7.02M | 9.96%6.98M |
| Deferred tax | 13.96%19.15M | 14.51%13.96M | 11.96%2.65M | 194.12%160K | -1.49%2.38M | -27.58%16.8M | 48.71%12.19M | 223.02%2.37M | -102.99%-170K | -78.52%2.42M |
| Other non cash items | ---- | ---- | ---- | ---- | ---- | ---15.29M | ---- | ---- | ---- | ---- |
| Change In working capital | 174.13%28.1M | -94.65%2.16M | 197.95%4.64M | 136.92%30.15M | 89.74%-8.85M | 86.41%-37.91M | 745.92%40.27M | 97.89%-4.73M | 113.84%12.73M | -296.97%-86.17M |
| -Change in receivables | 1.23%40.21M | -70.58%11.06M | -70.50%-2.64M | 139.16%56.1M | -22.85%-24.31M | 440.09%39.72M | 426.30%37.6M | 89.36%-1.55M | 15.61%23.46M | -235.79%-19.79M |
| -Change in inventory | 228.40%21.73M | 318.35%9.96M | 6.50%-6.59M | -389.68%-3.62M | 434.71%21.98M | -717.88%-16.92M | -5,465.88%-4.56M | -1,561.62%-7.05M | 1,938.24%1.25M | -155.69%-6.57M |
| -Change in payables and accrued expense | 44.26%-33.84M | -360.92%-18.87M | 259.20%13.87M | -86.36%-22.32M | 89.11%-6.51M | 77.12%-60.71M | 38.95%7.23M | 101.83%3.86M | 89.32%-11.98M | -214.57%-59.82M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 292.30%124.56M | -32.33%38.34M | 142.23%30.93M | 133.37%47.52M | 113.40%7.78M | 120.01%31.75M | 37.31%56.65M | 106.65%12.77M | 139.14%20.36M | -231.90%-58.03M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 167.18%84.34M | -957.00%-57.2M | 184.91%81.67M | 239.23%98.57M | -211.36%-38.7M | 26.40%-125.56M | 106.15%6.67M | -586.00%-96.19M | -124.56%-70.79M | 311.57%34.76M |
| Net PPE purchase and sale | -176.02%-53.97M | 31.37%-5.74M | -344.65%-34.43M | -411.83%-7.01M | -227.53%-6.79M | 82.40%-19.55M | 91.79%-8.37M | -135.35%-7.74M | 30.72%-1.37M | 46.20%-2.07M |
| Net intangibles purchase and sale | 15.99%-247K | 13.95%-148K | 9.26%-49K | 102.94%1K | -50.00%-51K | -20.99%-294K | -39.84%-172K | -315.38%-54K | 2.86%-34K | 52.78%-34K |
| Net business purchase and sale | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net investment purchase and sale | 231.08%138.56M | -437.25%-51.31M | 231.40%116.15M | 252.15%105.58M | -186.43%-31.86M | -58.56%-105.71M | 209.16%15.21M | -724.65%-88.39M | -135.10%-69.39M | 394.90%36.86M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 167.18%84.34M | -957.00%-57.2M | 184.91%81.67M | 239.23%98.57M | -211.36%-38.7M | 26.40%-125.56M | 106.15%6.67M | -586.00%-96.19M | -124.56%-70.79M | 311.57%34.76M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0 | |||||||||
| Net common stock issuance | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | ---- | ---- | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | -38.48%154.5M | 315.78%382.41M | 53.55%269.01M | -45.01%124.17M | -38.48%154.5M | -58.50%251.13M | -71.09%91.97M | -66.55%175.19M | -63.28%225.8M | -58.50%251.13M |
| Current changes in cash | 322.69%208.9M | -129.78%-18.86M | 234.97%112.6M | 389.66%146.09M | -32.89%-30.93M | 73.52%-93.81M | 194.03%63.32M | 59.49%-83.42M | 44.06%-50.43M | -351.68%-23.27M |
| Effect of exchange rate changes | 82.95%-483K | 20.20%-640K | 288.35%800K | -600.56%-1.24M | 128.98%597K | -1,766.47%-2.83M | -311.61%-802K | -47.18%206K | 83.35%-177K | -543.97%-2.06M |
| End cash Position | 134.90%362.91M | 134.90%362.91M | 315.78%382.41M | 53.55%269.01M | -45.01%124.17M | -38.48%154.5M | -38.48%154.5M | -71.09%91.97M | -66.55%175.19M | -63.28%225.8M |
| Free cash flow | 490.92%70.34M | -32.56%32.45M | -171.49%-3.55M | 113.68%40.51M | 101.55%933K | 104.41%11.9M | 179.11%48.11M | 102.55%4.97M | 135.09%18.96M | -250.09%-60.14M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
